Key clinical trials of maralixibat (Mirum Pharmaceuticals Inc.)

Identifier(s)	Indication	Phase	Drug(s)	Location(s)	Status
NCT02160782; ICONIC	Alagille syndrome	II	Maralixibat; placebo	Australia, Belgium, France, Poland, Spain, UK	Completed
NCT01903460; IMAGO	Alagille syndrome	II	Maralixibat; placebo	UK	Completed
NCT02047318; IMAGINE	Alagille syndrome	II	Maralixibat	UK	Completed
NCT02057692; ITCH	Alagille syndrome	II	Maralixibat; placebo	Canada, USA	Completed
NCT02117713; IMAGINE-II	Alagille syndrome	II	Maralixibat	Canada, USA	Completed
NCT02057718; INDIGO	PFIC	II	Maralixibat	France, Poland, UK, USA	Completed
NCT03905330; MARCH-PFIC	PFIC	III	Maralixibat; placebo	Multinational	Recruiting
NCT04185363; MARCH-ON	PFIC	III	Maralixibat	Multinational	Enrolling by invitation
NCT04168385; MERGE	Cholestatic liver disease	II	Maralixibat	Australia, Belgium, Canada, France, Poland, Spain, UK, USA	Enrolling by invitation
NCT04729751: RISE	Cholestatic liver disease	II	Maralixibat	Belgium, France, Poland, UK, USA	Recruiting
NCT04524390; EMBARK	Biliary atresia	II	Maralixibat; placebo	Germany, Poland, UK, USA	Recruiting

PFIC progressive familial intrahepatic cholestasis